February 13th 2025
Polypharmacy, biosimilars, and GLP-1s among the evolving trends likely to play out in the pharmacy benefits space.
Q&A With Miruna Sasu, president and CEO, COTA, Inc.
April 20th 2022From exposing disparities in care to guiding better patient outcomes to helping reign in the costs of care, the use of real-world data (RWD) in oncology can have far-reaching effects. Here’s how one RWD company exec is using her experience to help drive that change.
Q&A With Aoife Brennan, president and CEO of Synlogic, Inc.
March 16th 2022Brennan describes what her career journey in pharma has looked like as a woman, and what she feels can be done to improve opportunities for other females in pharma. She also talks about how advocacy and commitment can similarly be applied to improve the rare disease space.
An Inside Look at Handling Alliance Management
March 10th 2022Mary Jo Struttmann, executive director of alliance management for Astellas discusses how to form strategic partnerships to bring new drugs to market and how to navigate partnerships, alliance dynamics, and potential challenges in 2022 and beyond.
Striking a Balance of Digital and Physical Assets for Growth
February 22nd 2022In this installment of the Harvard Business School Healthcare Alumni Association (HBSHAA) Q&A series, Michael Wong talks to Robert E. Siegel, lecturer in management at the Stanford Graduate School of Business, about determining the optimal combination of digital and physical assets for an S&P 500’s growth playbook.
Preparing Millennials for Their Inevitable Career Changes
February 4th 2022Joseph A. DiAngelo, EdD, dean of the Erivan K. Haub School of Business at Saint Joseph’s University (SJU), discusses how the school’s programs reinforce real-world lessons and prepare younger generations to deal with a career environment in flux.